What are the low‑dose aspirin recommendations for an adult without known atherosclerotic disease based on age and coronary calcium score from CT?

Aspirin Recommendations Based on Age and Coronary Calcium Score

For primary prevention in adults without known atherosclerotic disease, aspirin should NOT be routinely recommended based on age alone—instead, use coronary artery calcium (CAC) scoring to guide therapy: prescribe low-dose aspirin (75-100 mg daily) only when CAC ≥100 AND the patient is age 40-70 years with ASCVD risk ≥5% and low bleeding risk. 1, 2

Age-Based Framework

Age <40 Years

• Do not prescribe aspirin for primary prevention regardless of CAC score
• Insufficient evidence to support use in this age group
• Bleeding risk outweighs cardiovascular benefit 1, 3

Age 40-70 Years: Use CAC-Guided Approach

This is where CAC scoring provides the most clinical value for aspirin decision-making:

CAC = 0:

• Do not prescribe aspirin
• CAC of 0 is the strongest negative predictor for cardiovascular events
• Number needed to treat (NNT) is 1,190 vs number needed to harm (NNH) of 567—clear net harm 2, 4
• This applies even if calculated ASCVD risk appears elevated

CAC 1-99:

• Generally do not prescribe aspirin
• Intermediate calcium burden does not justify bleeding risk in most cases
• Consider only if ASCVD risk >10% AND no bleeding risk factors 5, 2

CAC ≥100:

• Prescribe aspirin 75-100 mg daily if:
  • 10-year ASCVD risk ≥5% (borderline or higher)
  • No increased bleeding risk (no history of GI bleeding, not on anticoagulation, no anemia, no renal disease)
• NNT of 140 vs NNH of 518—favorable benefit-harm ratio 2
• This threshold identifies advanced subclinical atherosclerosis warranting intervention 5, 6

CAC ≥400:

• Strongly recommend aspirin unless contraindicated
• Very high atherosclerotic burden
• Even more favorable NNT:NNH ratio 2

Age >70 Years

• Do not prescribe aspirin for primary prevention regardless of CAC score
• Bleeding risk substantially exceeds cardiovascular benefit in this age group
• The ASCEND and ASPREE trials demonstrated net harm in elderly patients 1, 3, 7

Critical Bleeding Risk Assessment

Before prescribing aspirin at any age or CAC level, exclude these high bleeding risk factors:

• Age >70 years
• History of gastrointestinal bleeding or peptic ulcer disease
• Concurrent anticoagulation therapy
• Chronic kidney disease (particularly if GFR <30)
• Anemia
• Thrombocytopenia
• Concurrent NSAID use

• 3 alcoholic drinks daily 1, 8

If ANY high bleeding risk factor is present, do not prescribe aspirin regardless of CAC score or ASCVD risk. 5

Dosing Specifics

When aspirin is indicated:

• Dose: 75-100 mg daily (81 mg is standard U.S. formulation)
• No evidence supports higher doses for primary prevention
• The ADAPTABLE trial showed no difference between 81 mg and 325 mg for efficacy or bleeding 3, 9
• Take with full glass of water to reduce GI irritation 8

Why CAC Outperforms Traditional Risk Calculators

The pooled cohort equations (PCE) alone are insufficient for aspirin decisions:

• Using PCE risk >20% alone: overall NNT of 476 vs NNH of 355 (net harm) 2
• CAC ≥100 identifies patients with actual atherosclerotic plaque burden, not just risk factors
• CAC provides direct visualization of disease, making it superior to calculated risk 2, 4, 10

Common Pitfalls to Avoid

1. Do not prescribe aspirin based solely on diabetes status: The 2023 ADA guidelines moved away from routine aspirin in diabetics after the ASCEND trial showed equal bleeding and cardiovascular events 3, 1

2. Do not use aspirin in patients >70 years thinking "high risk justifies it": Age >70 is an absolute relative contraindication for primary prevention 1, 7

3. Do not skip CAC scoring in intermediate-risk patients: Traditional risk calculators misclassify many patients; CAC reclassifies risk more accurately 2, 4

4. Do not continue aspirin indefinitely without reassessing bleeding risk: Bleeding risk increases with age and comorbidities 1

When CAC Scoring Is Most Useful

Order CAC scoring for aspirin decision-making in:

• Adults 40-70 years with borderline ASCVD risk (5-7.5%)
• Adults 40-70 years with intermediate ASCVD risk (7.5-20%)
• Adults with diabetes age 40-70 years when considering primary prevention 1, 11, 4

Do not order CAC if: Patient is <40 years, >70 years, has established ASCVD (already needs aspirin for secondary prevention), or has clear contraindications to aspirin 11, 7

Shared Decision-Making Points

When CAC ≥100 and aspirin is being considered, discuss with patients:

• Absolute risk reduction: approximately 12% relative risk reduction in cardiovascular events over 7-10 years 3, 1
• Bleeding risk: approximately 29-42% relative increase in major bleeding, mostly GI 1
• For every 140 patients treated, prevent 1 cardiovascular event but cause 1 major bleed in every 518 patients (when CAC ≥100) 2
• Emphasize that optimal control of blood pressure, lipids, and glucose remains more important than aspirin 7